/UCBJY

UCBJY Stock - UCB S.A.

Q: What is the analyst price target for UCBJY?

Analyst price target information is not currently available for UCBJY.

Q: What is UCBJY's market cap?

Market capitalization information is not currently available for UCBJY.

Healthcare|Biotechnology|OTC

$141.02+1.97%

+$2.72 (+1.97%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $155.12

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for UCBJY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.22

52W High$151.75

52W Low$71.16

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$6.15B	$5.25B	$5.52B	$5.78B	$5.35B
Gross Profit	$4.40B	$3.54B	$3.84B	$4.34B	$3.98B
Gross Margin	71.5%	67.5%	69.6%	75.1%	74.5%
Operating Income	$1.32B	$604.00M	$585.00M	$1.28B	$971.00M
Net Income	$1.06B	$343.00M	$418.00M	$1.06B	$732.00M
Net Margin	17.3%	6.5%	7.6%	18.3%	13.7%
EPS	$2.81	$0.88	$1.10	$2.80	$1.94

Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 26th 2023	Jefferies	Downgrade	Hold	-
May 31st 2023	UBS	Initiation	Buy	-

Earnings History & Surprises

UCBJY

Beat Rate

75%

Last 12 quarters

Avg Surprise

+52.5%

EPS vs Estimate

Beats / Misses

9/3

Last 12 quarters

Latest EPS

$1.44

Q3 2025

EPS Surprise History

Q4 21

+91.3%

$2.85vs$1.49

Q2 22

+69.8%

$2.14vs$1.26

Q4 22

-73.6%

$0.11vs$0.40

Q2 23

+86.5%

$1.74vs$0.93

Q2 24

-75.9%

$0.18vs$0.73

Q3 24

+20.7%

$1.15vs$0.95

Q1 25

+237.8%

$4.56vs$1.35

Q3 25

-25.4%

$1.44vs$1.93

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 25, 2026	—	—	—	—
Q3 2025	Jul 31, 2025	$1.93	$1.44	-25.4%	✗ MISS
Q1 2025	Feb 27, 2025	$1.35	$4.56	+237.8%	✓ BEAT
Q3 2024	Jul 25, 2024	$0.95	$1.15	+20.7%	✓ BEAT
Q2 2024	Jun 12, 2024	$0.73	$0.18	-75.9%	✗ MISS
Q2 2023	Jun 30, 2023	$0.93	$1.74	+86.5%	✓ BEAT
Q4 2022	Dec 31, 2022	$0.40	$0.11	-73.6%	✗ MISS
Q2 2022	Jun 30, 2022	$1.26	$2.14	+69.8%	✓ BEAT
Q4 2021	Dec 31, 2021	$1.49	$2.85	+91.3%	✓ BEAT
Q2 2021	Jun 30, 2021	$1.81	$3.48	+92.3%	✓ BEAT
Q4 2020	Dec 31, 2020	$1.23	$2.27	+84.6%	✓ BEAT
Q2 2020	Jun 30, 2020	$1.50	$2.16	+44.0%	✓ BEAT
Q4 2019	Dec 31, 2019	$1.29	$2.29	+77.5%	✓ BEAT
Q2 2019	Jun 30, 2019	—	$2.49	—	—
Q4 2018	Dec 31, 2018	—	$1.58	—	—
Q2 2018	Jun 30, 2018	—	$3.39	—	—
Q4 2017	Dec 31, 2017	—	$2.01	—	—
Q2 2017	Jun 30, 2017	—	$2.61	—	—
Q4 2016	Dec 31, 2016	—	$1.30	—	—
Q2 2016	Jun 30, 2016	—	$1.83	—	—